Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.

Also called NCT04707352

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 162 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04707352
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04707352. Allocation not applicable; no masking; primary purpose treatment. Start 2021-02-08 (actual); primary completion 2023-03-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .
Acronym
MODA
Condition
Heart Failure
Intervention (Drug)
Dapagliflozin
Lead sponsor
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia (class: other)
Collaborator
Spanish Society of Cardiology (class: other)

Record details

Record id
cardio:ct-nct04707352
Content hash
ff30d006071f7ef2c955616c57dc4b7ef225e6425266cfe2fd8a77c99fe4f8c7